Publications by authors named "C Oliani"
Article Synopsis
- A multidisciplinary group of 69 experts created the first evidence-based consensus recommendations for managing early-onset colorectal cancer (eoCRC) since existing guidelines are not age-specific.
- They utilized a Delphi methodology, achieving an 80% consensus on 31 important statements covering diagnosis, genetics, therapy, and more, emphasizing the need for risk stratification and genetic testing for patients under 50.
- The recommendations highlight that treatments for eoCRC should generally align with those for later-onset cases, but also point out knowledge gaps that require further research, including optimal screening age and post-treatment care.
Background: Real-world (RW) evidence on nivolumab in pretreated patients with non-small cell lung cancer (NSCLC) by matching data from administrative health flows (AHFs) and clinical records (CRs) may close the gap between pivotal trials and clinical practice.
Methods: This multicenter RW study aims at investigating median time to treatment discontinuation (mTTD), overall survival (mOS) of nivolumab in pretreated patients with NSCLC both from AHF and CR; clinical-pathological features predictive of early treatment discontinuation (etd), budget impact (BI), and cost-effectiveness analysis were investigated; mOS in patients receiving nivolumab and docetaxel was assessed.
Results: Overall, 237 patients with NSCLC treated with nivolumab were identified from AHFs; mTTD and mOS were 4.
Introduction: We analyzed a cohort of patients with cancer and Sars-Cov-2 infection from the Veneto Oncology Network registry across two pandemic time periods.
Materials And Methods: 761 patients with cancer and SARS-CoV-2 infection were included.
Results: 198 patients were diagnosed during the first pandemic time period (TP1; February 2020 September 2020), 494 during TP2 before the vaccination campaign (TP2/pre-vaccination; September 2020-21 February 2021) and 69 in TP2/post-vaccination (22 February 2021-15 May 2021).
Cancer prevention in the era of precision medicine has to consider integrated therapeutic approaches. Therapeutic cancer prevention should be offered to selected cohorts with increased cancer risk. Undoubtedly, carriers of hereditary cancer syndromes have a well-defined high cancer risk.
View Article and Find Full Text PDF